IMMIX BIOPHARMA, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value
IMMIX BIOPHARMA, INC. (IMMX) had Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value of $289.08 thousand as of 2025-03-31, per its 10-Q filed 2025-05-08.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue · last filed 2025-05-08
- 2025-03-31: Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value $289.08K.
- 2024-12-31: Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value $1.19M.
- 2024-09-30: Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value $200.68K.
- 2024-06-30: Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value $499.99K.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value |
|---|---|
| 2025-03-31 | $289.08K 10-Q · filed 2025-05-08 |
| 2024-12-31 | $1.19M 10-K · filed 2025-03-25 |
| 2024-09-30 | $200.68K 10-Q · filed 2024-11-12 |
| 2024-06-30 | $499.99K 10-Q · filed 2024-08-12 |
| 2024-03-31 | $1.80M 10-Q · filed 2024-05-09 |
| 2023-12-31 | $6.42M 10-K · filed 2024-03-29 |
| 2023-09-30 | $1.87M 10-Q · filed 2023-11-13 |
| 2023-06-30 | $1.02M 10-Q · filed 2023-08-11 |
| 2023-03-31 | $335.11K 10-Q · filed 2023-05-12 |
| 2022-12-31 | $603.29K 10-K · filed 2023-03-27 |
| 2022-09-30 | $111.76K 10-Q · filed 2022-11-09 |
| 2022-06-30 | $622.50K 10-Q · filed 2022-08-12 |
| 2022-03-31 | $600.34K 10-Q · filed 2022-05-13 |
| 2021-12-31 | $1.08M 10-K · filed 2022-03-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Cryoport, Inc. (CYRX) | United States | $0.881B | -21.29 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 |